Description:FIELD OF INVENTION
The present invention relates to a novel nutraceutical formulation for children, comprising proteins, vitamins, minerals, herbal extracts, and dietary fibers. It particularly emphasizes the synergistic role of Garcinia mangostana (mangosteen) and Plantago ovata in enhancing growth, immunity, cognition, and digestive health. The invention further pertains to stable, bioavailable, and child-friendly compositions in powder or similar dosage forms
BACKGROUND OF THE INVENTION
Children in their growing years often face nutritional gaps due to irregular diets, poor intake of essential proteins, vitamins, and minerals, and exposure to processed foods. Such deficiencies manifest as stunted growth, weak immunity, digestive discomfort, and poor cognitive performance. Conventional protein powders or supplements are largely designed for adults and fail to address the multi-dimensional nutritional needs of children, especially when it comes to immune modulation, gut support, and antioxidant protection.
Existing pediatric supplements typically provide single-dimensional benefits—either focusing on proteins for growth, or vitamins and minerals for bone health. However, they rarely integrate bioactive herbal extracts with proven antioxidant and anti-inflammatory activities. This limitation leads to partial outcomes, where children may gain macronutrients but continue to suffer from frequent infections, digestive imbalances, or low energy. Additionally, stability and palatability remain key challenges in pediatric nutraceuticals, often resulting in poor compliance.
To overcome these problems, the present invention introduces a child-friendly nutraceutical composition—Renatus XanthPro Protein Powder (Kids). By combining protein isolates with Garcinia mangostana (rich in xanthones), Plantago ovata fiber, vitamins, and minerals, the formulation not only supports growth and bone health but also enhances immunity, cognitive performance, and digestive function. The cold press extraction and homogenization methods ensure bioavailability and long-term stability, offering a scientifically validated solution to multi-faceted nutritional deficiencies in children.
OBJECTS OF THE INVENTION
Some of the objects of the present disclosure, which at least one embodiment herein satisfies, are as follows.
It is an object of the present disclosure to ameliorate one or more problems of the prior art or to at least provide a useful alternative
An object of the present disclosure is to provide a child-specific nutraceutical composition that addresses multi-dimensional needs such as growth, immunity, cognition, and digestive health.
Another object of the present disclosure is to develop a synergistic formulation combining proteins, minerals, vitamins, and herbal extracts, offering benefits beyond a mere admixture.
Still another object of the present disclosure is to deliver superior antioxidant protection through mangosteen-derived xanthones, thereby reducing oxidative stress in growing children.
Another object of the present disclosure is to provide anti-inflammatory support that aids in faster tissue repair and recovery from infections or minor injuries.
Still another object of the present disclosure is to enhance immune function by stimulating T-cell activity, macrophage phagocytosis, and gut microbiota balance via Plantago ovata fiber.
Still another object of the present disclosure is to offer antimicrobial protection against common pathogens, while ensuring stability of actives in gastric conditions.
Yet another object of the present disclosure is to provide cytoprotective and neuroprotective effects, maintaining higher neuronal survival under oxidative stress.
Yet another object of the present disclosure is to improve calcium absorption and skeletal strength in children through the synergistic action of Vitamin D3 and minerals.
Yet another object of the present disclosure is to ensure the formulation remains stable and bioavailable for up to three years under ambient storage conditions.
Yet another object of the present disclosure is to provide a palatable, child-friendly nutraceutical composition in powder form that ensures higher compliance and acceptability.

Other objects and advantages of the present disclosure will be more apparent from the following description, which is not intended to limit the scope of the present disclosure.

SUMMARY OF THE INVENTION
The following presents a simplified summary of the invention in order to provide a basic understanding of some aspects of the invention. This summary is not an extensive overview of the present invention. It is not intended to identify the key/critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some concept of the invention in a simplified form as a prelude to a more detailed description of the invention presented later.

The present invention is generally directed to a child-oriented nutraceutical composition that integrates proteins, vitamins, minerals, and herbal extracts. The formulation is specifically designed to support growth, immunity, cognition, and digestive health in children.

An embodiment of the present invention relates to the inclusion of Garcinia mangostana pericarp extract, rich in xanthones, which provides potent antioxidant, anti-inflammatory, and cytoprotective effects.

Another embodiment of the invention provides Plantago ovata husk as a dietary fiber source that promotes digestive health and probiotic growth. This indirectly strengthens immune function and complements the protein blend for balanced nutrition.

Yet another embodiment of the invention is the incorporation of calcium carbonate, magnesium oxide, and Vitamin D3, which together improve skeletal strength, calcium absorption, and bone growth.

Yet another embodiment of the invention is its standardized formulation and manufacturing process, including cold press extraction, homogenization, and stability validation. This ensures a shelf life of up to three years and maintains consistency, safety, and efficacy of the composition.

Yet another embodiment of the invention is a pediatric nutraceutical composition for promoting growth, immunity, cognition, and digestive health in children, the composition comprising:
Garcinia mangostana pericarp extract in an amount of 100 to 250 mg;
calcium carbonate in an amount of 300 to 350 mg; magnesium oxide in an amount of 100 to 150 mg;
cholecalciferol (vitamin D3) in an amount of 400 to 450 IU;
a protein blend comprising soy and/or whey protein isolates and concentrates in an amount of 10 to 15 g;
Plantago ovata husk powder in an amount of 2 to 10 g;
and one or more natural flavoring agents in a quantity sufficient to enhance palatability;
wherein the composition demonstrates synergistic antioxidant activity with IC₅₀ value of 15 µg/mL; and composition is stable for 3 years.

Yet another embodiment of the invention is wherein the Garcinia mangostana pericarp extract is obtained through cold press extraction at temperatures not exceeding 40°C under hydraulic pressure of 200-300 bar for 2-4 hours, followed by membrane filtration through 0.45μm filters and concentration under reduced pressure to preserve thermolabile bioactive compounds.

Yet another embodiment of the invention is wherein the protein blend is processed through cryogenic grinding to achieve uniform particle sizes below 10 micrometer
Yet another embodiment of the invention is wherein the Plantago ovata husk demonstrates prebiotic activity by promoting growth of beneficial Lactobacillus species by 35%.
Yet another embodiment of the invention is wherein the method for preparing the nutraceutical composition as claimed in claim 1, comprising the sequential steps of: (a) subjecting protein isolates to cryogenic grinding and micronization to achieve particle sizes below 10 micrometers;
(b) sequentially incorporating calcium carbonate and magnesium oxide using gentle blending at 200-300 RPM for 5 to 7 minutes;
(c) integrating cold-pressed Garcinia mangostana pericarp extract and Plantago ovata husk powder through graduated mixing at 300 to 500 RPM for 8to 10 minutes;
(d) incorporating cholecalciferol via microencapsulation technique under nitrogen atmosphere at 150 to 250 RPM for 3 to 5 minutes;
(e) adding natural flavoring agents followed by high-shear homogenization at 800-1200 RPM for 15 to 20 minutes while maintaining temperature below 25°C and relative humidity below 45%;
(f) conducting final homogenization at 1200 to 1500 RPM for 10 to 15 minutes; and
(g) packaging in hermetically sealed multi-layer jars to ensure stability and prevent degradation over the validated 36-month shelf life.

DETAILED DESCRIPTION OF THE INVENTION
The following description is of exemplary embodiments only and is not intended to limit the scope, applicability or configuration of the invention in any way. Rather, the following description provides a convenient illustration for implementing exemplary embodiments of the invention. Various changes to the described embodiments may be made in the function and arrangement of the elements described without departing from the scope of the invention.

BIOLOGICAL SOURCE:
Herbal extracts such as Garcinia mangostana and Plantago ovata are procured from surrounding areas of Kolkata, west Bengal.

EXAMPLE 1: COMPOSITION
Ingredient Latin Name Quantity Part Used
Mangosteen Garcinia mangostana 100–250 mg Pericarp
Calcium Calcium carbonate 300–350 mg Mineral
Magnesium Magnesium oxide 100–150 mg Mineral
Vitamin D3 Cholecalciferol 400–450 IU –
Protein Blend – 10–15 g –
Dietary Fiber Plantago ovata 2–10 g Husk
Natural Flavour – q.s. –

EXAMPLE 2: FORMULATION AND MANUFACTURING PROCESS
The manufacturing process has been designed to achieve product homogeneity, enhanced bioavailability, and long-term stability of up to three years

A method for preparing a stable pharmaceutical-grade nutraceutical composition comprises selecting raw materials including mangosteen pericarp (Garcinia mangostana L.) standardized for xanthone content, Plantago ovata husk with minimum 85% mucilage, protein isolates exceeding 90% purity, pharmaceutical-grade mineral salts, stabilized vitamin D3, and natural flavoring agents to improve palatability and nutritional synergy.

The method further comprises performing cold press extraction of mangosteen pericarp and Plantago husk at temperatures not exceeding 40°C under hydraulic pressure of 200-300 bar for 2-4 hours, filtering through 0.45μm membranes, concentrating under reduced pressure, and simultaneously conducting cryogenic grinding and jet milling of protein isolates and mineral salts to achieve particle sizes below 10μm for enhanced bioavailability.
Step 1: Primary base preparation begins with protein isolates (10-15 g) being subjected to cryogenic grinding and micronization to achieve particle sizes below 10 micrometers, followed by sieving through 80-120 mesh to ensure uniform distribution as the foundational matrix.
Step 2: Mineral salts addition involves sequential incorporation of calcium carbonate (300-350 mg) and magnesium oxide (100-150 mg) into the protein base using gentle blending at 200-300 RPM for 5-7 minutes to prevent electrostatic aggregation and ensure homogeneous mineral distribution.
Step 3: Herbal extract integration comprises adding cold-pressed Garcinia mangostana pericarp extract (100-250 mg) standardized for xanthone content, followed by Plantago ovata husk powder (2-10 g) with minimum 85% mucilage content, blended at increasing speeds from 300-500 RPM for 8-10 minutes.
Step 4: Vitamin D3 stabilization involves incorporating cholecalciferol (400-450 IU) through specialized microencapsulation technique using protective carriers to prevent oxidation, added during low-speed mixing at 150-250 RPM for 3-5 minutes under nitrogen atmosphere.
Step 5: Flavor enhancement and final homogenization includes addition of natural flavoring agents (q.s.) for child acceptability, followed by high-shear mixing at 800-1200 RPM for 15-20 minutes while maintaining temperature below 25°C and relative humidity below 45%.
Step 6: Final homogenization cycle involves complete formulation blending at 1200-1500 RPM for 10-15 minutes, followed by immediate packaging under controlled atmospheric conditions to maintain ingredient stability and prevent segregation during storage.
Rigorous quality checks, including HPLC fingerprinting of herbal actives, ICP-MS analysis of minerals, and microbiological safety testing, are conducted at multiple stages. Finally, the formulation is packed in hermetically sealed sachets and jars to protect against moisture and oxidation, ensuring both stability and efficacy throughout its shelf life.

EXAMPLE 3: ANTIOXIDANT ACTIVITY
The antioxidant potential of the mangosteen pericarp extract was evaluated using multiple in-vitro assays. In the DPPH radical scavenging assay, the extract demonstrated an IC50 value of 12.4 µg/mL, which was superior to that of ascorbic acid (18.6 µg/mL), confirming strong free radical neutralization capacity. The ABTS assay further showed 88.5% radical inhibition at a concentration of 100 µg/mL. When the mangosteen extract was blended with protein isolates, the overall antioxidant capacity of the formulation improved by 22% in the FRAP assay, establishing the synergistic effect of the protein–herbal combination.

EXAMPLE 4: ANTI-INFLAMMATORY ACTIVITY
The anti-inflammatory properties of mangosteen-derived xanthones were assessed in RAW 264.7 macrophage models. At a concentration of 50 µg/mL, the extract inhibited nitric oxide (NO) production by 72%, while secretion of pro-inflammatory cytokines IL-6 and TNF-α was reduced by 65% and 59% respectively in LPS-stimulated cells. Additionally, protein supplementation within the formulation accelerated cellular repair mechanisms, as demonstrated by a 30% faster wound closure rate in in-vitro scratch assays, highlighting its dual role in inflammation control and tissue regeneration.

EXAMPLE 5: IMMUNOMODULATORY ACTIVITY
The immunomodulatory activity of mangosteen xanthones was confirmed through lymphocyte and macrophage assays. T-lymphocyte proliferation increased by 48% in treated groups compared to untreated controls. Similarly, the phagocytic index of macrophages increased by 1.7-fold in the presence of 20 µg/mL mangosteen extract, indicating enhanced innate immune activity. Furthermore, Plantago ovata fiber promoted a 35% increase in the growth of beneficial Lactobacillus species, indirectly supporting gut-mediated immune modulation, thereby providing holistic immunoprotective effects.

EXAMPLE 6: ANTIMICROBIAL ACTIVITY
The antimicrobial activity of mangosteen extract was studied against bacterial and fungal strains using agar diffusion and MIC assays. At 100 µg/mL concentration, inhibition zones of 18.2 mm, 16.5 mm, and 14.8 mm were observed against Staphylococcus aureus, Escherichia coli, and Candida albicans respectively. The corresponding MIC values were 62.5 µg/mL for S. aureus, 75 µg/mL for E. coli, and 80 µg/mL for C. albicans. Incorporation of protein carriers into the formulation improved the stability of the extract, reducing degradation in simulated gastric fluid by 27%, thereby ensuring antimicrobial efficacy post ingestion.

EXAMPLE 7: CYTOPROTECTIVE AND GROWTH-SUPPORTING EFFECTS
Cytoprotective properties of the formulation were validated using neuronal and intestinal cell models. In SH-SY5Y neuronal cells exposed to oxidative stress (H2O2), mangosteen xanthones maintained 82% cell survival, demonstrating potent neuroprotective effects. Gut epithelial Caco-2 cells exhibited a 41% increase in viability in the presence of XanthPro formulation extracts, confirming intestinal protection. Moreover, supplementation with 400 IU of Vitamin D3 significantly enhanced calcium uptake in Caco-2 intestinal transport assays by 38%, thereby supporting both bone growth and systemic development in children.

Activity Mangosteen (Hero) Results Synergistic Formulation Effects
Antioxidant IC50 (DPPH) = 12.4 µg/mL; ABTS inhibition = 88.5% FRAP assay: +22% antioxidant capacity with protein
Anti-inflammatory 72% NO inhibition; IL-6 ↓65%; TNF-α ↓59% 30% faster wound closure
Immunomodulatory T-cell proliferation ↑48%; Phagocytosis ↑1.7-fold Probiotic growth ↑35%
Antimicrobial Inhibition zones: 18.2 mm (S. aureus), 16.5 mm (E. coli) Protein stabilizes actives; ↓27% degradation
Cytoprotective 82% neuronal survival under oxidative stress Calcium uptake ↑38% with Vitamin D3
The in-vitro studies of the formulation demonstrated strong antioxidant activity, with mangosteen pericarp extract showing an IC50 value of 12.4 µg/mL in the DPPH assay and 88.5% inhibition in the ABTS assay. When combined with protein isolates, the formulation exhibited a 22% increase in overall antioxidant capacity as confirmed by FRAP analysis, indicating clear synergistic benefits.
Anti-inflammatory evaluation revealed that mangosteen xanthones effectively inhibited nitric oxide production by 72% in macrophage models, while also reducing IL-6 and TNF-α levels by 65% and 59% respectively. Importantly, the protein component of the formulation accelerated wound repair, leading to a 30% faster wound closure rate in scratch assays, thus validating both anti-inflammatory and tissue-healing potential.
Immunomodulatory activity was also significant, as T-lymphocyte proliferation increased by 48% and macrophage phagocytic activity improved by 1.7-fold in the presence of mangosteen extract. The inclusion of Plantago ovata fiber further enhanced gut health by promoting a 35% increase in probiotic growth, thereby supporting immunity through both systemic and intestinal mechanisms.
The formulation exhibited potent antimicrobial properties, with inhibition zones of 18.2 mm against Staphylococcus aureus and 16.5 mm against Escherichia coli. Minimum inhibitory concentrations (MIC) confirmed the effectiveness of mangosteen extract against bacterial and fungal strains. Additionally, protein carriers improved stability, reducing degradation of active compounds by 27% in simulated gastric conditions.
Finally, cytoprotective studies highlighted that mangosteen xanthones maintained 82% neuronal survival under oxidative stress, while intestinal Caco-2 cells showed a 41% increase in viability in the presence of the formulation. Supplementation with 400 IU Vitamin D3 further enhanced calcium absorption by 38%, confirming the formulation’s role in supporting both neuroprotection and skeletal growth in children.
While considerable emphasis has been placed herein on the specific features of the preferred embodiment, it will be appreciated that many additional features can be added and that many changes can be made in the preferred embodiment without departing from the principles of the disclosure. These and other changes in the preferred embodiment of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.
, Claims:We Claim,
1. A pediatric nutraceutical composition for promoting growth, immunity, cognition, and digestive health in children, the composition comprising:
a) Garcinia mangostana pericarp extract in an amount of 100 to 250 mg;
b) calcium carbonate in an amount of 300 to 350 mg; magnesium oxide in an amount of 100 to 150 mg;
c) cholecalciferol-vitamin D3 in an amount of 400 to 450 IU;
d) a protein blend comprising soy and/or whey protein isolates and concentrates in an amount of 10 to 15 g;
e) Plantago ovata husk powder in an amount of 2 to 10 g;
f) and one or more natural flavoring agents in a quantity sufficient to enhance palatability;
g) wherein the composition demonstrates synergistic antioxidant activity with IC₅₀ value of 15 µg/mL; and composition is stable for 3 years.
2. The pediatric nutraceutical composition as claimed in claim 1, wherein the Garcinia mangostana pericarp extract is obtained through cold press extraction at temperatures not exceeding 40°C under hydraulic pressure of 200-300 bar for 2-4 hours, followed by membrane filtration through 0.45μm filters and concentration under reduced pressure to preserve thermolabile bioactive compounds.
3. The pediatric nutraceutical composition as claimed in claim 1, wherein the protein blend is processed through cryogenic grinding to achieve uniform particle sizes below 10 micrometer
4. The pediatric nutraceutical composition as claimed in claim 1, wherein the Plantago ovata husk demonstrates prebiotic activity by promoting growth of beneficial Lactobacillus species by 35%.
5. The pediatric nutraceutical composition of claim 1, wherein said composition is formulated into multiple pediatric-friendly dosage forms such as powder, capsules, granules, and suspensions.
6. A method for preparing the pediatric nutraceutical composition as claimed in claim 1, comprising the sequential steps of: (a) subjecting protein isolates to cryogenic grinding and micronization to achieve particle sizes below 10 micrometers;
(b) sequentially incorporating calcium carbonate and magnesium oxide using gentle blending at 200-300 RPM for 5 to 7 minutes;
(c) integrating cold-pressed Garcinia mangostana pericarp extract and Plantago ovata husk powder through graduated mixing at 300 to 500 RPM for 8to 10 minutes;
(d) incorporating cholecalciferol via microencapsulation technique under nitrogen atmosphere at 150 to 250 RPM for 3 to 5 minutes;
(e) adding natural flavoring agents followed by high-shear homogenization at 800-1200 RPM for 15 to 20 minutes while maintaining temperature below 25°C and relative humidity below 45%;
(f) conducting final homogenization at 1200 to 1500 RPM for 10 to 15 minutes; and
(g) packaging in hermetically sealed multi-layer jars to ensure stability and prevent degradation over the validated 36-month shelf life.

Dated this 15 September 2025

Dr. Amrish Chandra
Agent of the applicant
IN/PA No: 2959